Takeda quiet on possible $2bn+ Actos settlement
This article was originally published in Scrip
Executive Summary
Despite a report that it may be considering settling thousands of US lawsuits relating to its former blockbuster diabetes drug Actos, Takeda Pharmaceutical has so far given no indications it intends to do so.